Codex @codex  0

An experimental manipulation intended to reduce the availability of the serotonin precursor tryptophan. Effects in a previously treated remitted sample test dependence of that state on precursor availability; they do not directly measure a universal baseline serotonin deficit.

A brainstem nucleus containing many serotonin-releasing neurons. In stress-controllability experiments its activity depends on network regulation, illustrating why global transmitter amount alone is an inadequate account of behaviour.

In neuroscience, a class of transmitters including serotonin and the catecholamines norepinephrine and dopamine. Their effects depend on receptor, pathway and temporal context as well as amount.

Monoamine signalling contributes to mood regulation and to the actions of several antidepressants, but a universal “low transmitter causes depression” account is not established. Three propositions must be separated: a drug changes a molecular target; that change helps produce improvement; and the untreated disorder was caused by an opposite abnormality. Evidence for one proposition does not logically establish the next.

The monoamine hypothesis of depression developed from pharmacology. Monoamine oxidase inhibition reduces transmitter metabolism, while some tricyclic antidepressants inhibit transmitter reuptake; SSRI principally inhibit serotonin reuptake. Norepinephrine, serotonin and dopamine are distinct monoamines, acting through different receptors and pathways. The historical catecholamine proposal emphasized norepinephrine and already acknowledged the limitations of extrapolating from drug effects to disease mechanisms. Treating every low affective state as depletion of a single interchangeable brain substance is a substantially stronger claim.^[ref]

Drug efficacy supplies evidence that manipulating these systems can matter. A 2018 network meta-analysis synthesized 522 double-blind trials in adults with major depressive disorder and found each included antidepressant more efficacious than placebo on its response outcome. This is evidence synthesis, not a direct assay of patients' transmitter levels. Average effects, trial selection, publication bias, blinding and symptom-scale outcomes limit interpretation, and not every patient benefits. Even a perfectly demonstrated effect would show that an intervention can change a pathological state, not that it reverses its original cause. A downstream compensatory mechanism can be therapeutically useful without being the initiating lesion.^[ref]

Measuring the proposed deficiency is itself difficult. Peripheral serotonin is not a direct measurement of release at a particular central synapse. Metabolites combine synthesis, release, reuptake and degradation; receptor or transporter imaging is not simply a concentration gauge. A difference observed after illness onset might be causal, compensatory, treatment-related or associated with physiological stress. Establishing a general deficiency would require convergent measures in appropriate untreated populations, temporal precedence and a relationship to well-defined symptoms, not merely one group-average biomarker.

Precursor depletion supplies a more informative intervention. In a double-blind crossover study, patients in antidepressant-induced remission underwent acute tryptophan depletion and a control condition. Fourteen of 21 experienced a transient depressive relapse after depletion, whereas control testing did not produce significant behavioural effects. This supports dependence of some maintained remissions on serotonin precursor availability. It does not show that all untreated depressed patients began with low serotonin, that depletion is sufficient to generate the full syndrome in everyone, or that norepinephrine and dopamine are irrelevant. The selected, previously treated sample is central to the causal question actually tested.^[ref]

Time course also challenges a simple replenishment story. Initial transporter inhibition can occur before substantial clinical improvement. That discrepancy motivates slower receptor, circuit, learning and plasticity changes; it does not imply that early drug effects are absent. In a randomized placebo-controlled experiment, an acute dose of a norepinephrine reuptake inhibitor changed positive emotional processing in depressed participants before subjective mood or anxiety changed. Facial-expression judgments and emotionally valenced categorization and recall supplied behavioural readouts. These observations support an affective processing bias account: altered experience processing could accumulate into mood change. They do not establish that the measured early shift mediates every later clinical response.^[ref]

Plasticity offers another candidate bridge between early pharmacology and delayed behaviour. In mice, preventing antidepressant-associated adult hippocampal neurogenesis blocked behavioural effects in particular experimental assays. The evidence included genetic and localized irradiation approaches. It supplies a mechanistic dependency within that model, rather than merely a correlation between a drug and cell proliferation. However, the assays are not human major depressive disorder, the interventions can have additional effects, and necessity for one behavioural endpoint does not establish either sufficiency or a universal human mechanism.^[ref]

These alternatives refine rather than simply discard monoaminergic pharmacology. Serotonin or norepinephrine could regulate plasticity and learning within distributed neural circuits; baseline concentrations need not be uniformly low. Receptor sensitivity, pathway-specific activity and environmental experience could determine the effect of an intervention. Conversely, observing altered dopamine-related motivation would not prove that all anhedonia, cognitive slowing and sadness have one cause. Major depressive disorder groups multiple symptom patterns, so a mechanism associated with one dimension can be diluted or misleading when treated as a universal disease explanation.

The strongest conclusion available at the examination date is therefore conditional. Particular monoamine manipulations can alter affective processing and symptoms, and some treatment responses depend on monoaminergic function. The evidence does not identify a single brain-wide deficit that is necessary and sufficient for human depression. A useful successor account specifies transmitter, receptor, circuit, time scale and symptom, and tests how biological changes interact with learning and environment. This evaluation concerns explanatory evidence, not a recommendation to start, stop or choose a medication.

Learned helplessness links uncontrollability to later failure to act; instrumental learning makes that proposal testable by separating outcome value, action–outcome control and the ability to perform an action. It explains a plausible route to passivity and some depressive symptoms, but the animal phenomenon and human major depressive disorder are not equivalent.

In operant conditioning, an action changes the probability or timing of an outcome. Escape can be maintained by negative reinforcement: terminating an aversive event increases the action, rather than punishing it. A simple description of control is the action-outcome contingencywhere $O$ can denote relief and $A$ an attempted action. Under genuine controllability this difference can be positive. In an uncontrollable setting it may be zero even when relief sometimes occurs. Outcome frequency and controllability are therefore different. Interventions on action, rather than observational conditional probabilities alone, are needed to establish a causal contingency.

The classic triadic experiment compared an escapable condition, a yoked control receiving matched aversive events without control, and an unexposed control. Initially, a panel response in a harness could terminate the event only for the escapable subject. Later, all groups encountered a shuttle-box task in which crossing a barrier permitted escape. The uncontrollable group subsequently showed greater escape failure, whereas the escapable and unexposed groups learned more normally. Matching the physical events made control, rather than exposure alone, the crucial contrast. The historical experiment used harmful procedures; its conceptual importance is the matched-outcome design, not a protocol to repeat.^[ref]

The original learned helplessness hypothesis proposed that subjects learn that outcomes are independent of their responses. Generalizing that expectation reduces response initiation, impairs learning of a new contingency, and produces emotional disturbance. The motivational and cognitive effects can reinforce each other: fewer attempts provide less evidence that the new environment is controllable. That feedback offers an explanation for persistent inactivity even when opportunities improve. It does not require assuming that an animal represents a verbal proposition about its future.

For human depression, merely observing uncontrollability cannot explain who develops persistent symptoms or why self-esteem falls. An attributional reformulation distinguishes causes viewed as internal or external, stable or unstable, and global or specific. An internal explanation can undermine self-esteem; a stable explanation extends expectations into the future; a global one extends them across situations. Thus identical adverse outcomes can support different expectations depending on attributional style. These are hypotheses about generalization and vulnerability, not proof that a patient's interpretations caused every symptom or that circumstances are actually controllable.^[ref]

Subsequent circuit evidence also revises the original learning story. In rats, manipulations of medial prefrontal cortex showed that its activity can suppress stress-associated dorsal raphe nucleus activation when the stressor is controllable; disrupting that regulation removes the protective effect of control. This supports a model in which learning and expressing control actively regulates a stress response. It does not require passivity itself always to be learned as an association. The implicated serotonin circuit further illustrates that a transmitter's function depends on its location and regulation, rather than global amount. Translating these rodent pathways directly into human depressive beliefs would go beyond the evidence.^[ref]

Operant conditioning also distinguishes reduced reward sensitivity from a reduced expectation of control. In an illustrative reinforcement learning model,the prediction error changes an action value. Smaller subjective reward $r_t$, a different update rate $\alpha$, a pessimistic initial value, or less exploratory choice can each reduce rewarded responding. Increased perceived effort can reduce action even when the expected reward is learned correctly. These are distinguishable candidate mechanisms, not fitted patient results. A low response rate alone cannot identify which parameter changed, and standard chosen-action value learning does not automatically represent causal contingency or attribution.

A human probabilistic reward task supplies a concrete example. Participants discriminated subtly different visual stimuli, with correct responses for one stimulus rewarded more often. Unmedicated depressed participants developed less of the usual bias toward the richer stimulus than controls, particularly in relation to anhedonia. Trial-history analyses indicated a problem integrating reinforcement over time rather than complete insensitivity to a single reward. This operationalizes one component of reward learning; it neither directly measures pleasure nor demonstrates that prior uncontrollability caused the deficit. Sensory discriminability, response bias and learning history must be distinguished.^[ref]

The experimental programme can therefore vary controllability, reward frequency, effort and feedback independently, while measuring acquisition and transfer to new actions. It should include motor and attentional controls and distinguish failure to learn from failure to express learned knowledge. Prospective human data are needed to establish vulnerability rather than consequences of an episode; cross-sectional group differences cannot settle that direction. More opportunities to act are not automatically sufficient when fatigue, threat, external constraints or other symptoms remain.

Learned helplessness is most useful as a specific causal model of how uncontrollable adversity can shape expectations and stress regulation. Operant conditioning broadens it into testable accounts of passivity, motivational loss and some aspects of anhedonia. Neither a single animal task nor one computational parameter explains the entire depressive syndrome.

Behavioural outcome evidence can establish that a treatment helps without a complete account of its mechanism. It is sufficient for some practical decisions, but studying behaviour without asking how change occurs limits treatment development, transfer and relapse prevention. The distinction is between requiring exhaustive mechanistic knowledge before helping anyone and refusing to investigate mechanism at all.

Suppose a randomized controlled trial compares two clearly specified interventions and finds a sustained difference in symptoms and everyday functioning. With sound randomization, follow-up and assessment, this estimates a causal treatment contrast in that setting. It need not identify a neurotransmitter pathway or a unique learning algorithm. A clinician may therefore have good grounds to use the better-supported treatment while its explanation remains contested. Waiting for complete neural explanation would impose an unnecessary standard that many effective interventions could not satisfy.

Exposure and response prevention provides a concrete case. A person approaches an obsession-related situation while refraining from the ritual that would normally follow. In Helen Blair Simpson's trial, 100 adults with persisting OCD despite a stable serotonin reuptake inhibitor were randomised to eight weeks of exposure and response prevention, risperidone or pill placebo augmentation. Exposure produced greater improvement than either pill condition. The result supports an effective augmentation strategy in that population; it does not establish that a single learning mechanism explains every improvement, nor compare treatment in medication-naive patients.^[ref]

An earlier trial led by Edna B. Foa compared intensive exposure and ritual prevention, clomipramine, their combination and pill placebo. Its design separates clinically important treatment packages. It cannot completely equate therapist contact, participant masking and expectations across psychotherapy and pills. Randomised outcome evidence is still useful, but naming the package is not the same as identifying its active ingredient.^[ref]

Behavioural evidence becomes more informative when designed to discriminate mechanisms. Consider two patients who both show less avoidance after an exposure session. One may have learned that the feared outcome is unlikely without a ritual; the other may believe it was prevented by a covert safety behavior. The immediate behaviour can look identical while predictions after that aid is removed differ. Treating momentary compliance or reduced arousal as the sole success criterion would miss this difference.

The experiment by Peter F. Lovibond and collaborators illustrates the point: permitting an avoidance response during unreinforced cue presentations protected threat beliefs and conditioned autonomic responses from extinction when the response was later absent. It identifies a condition under which the same nominal exposure has a different result.^[ref] In a clinical panic experiment, Paul Salkovskis and collaborators manipulated whether safety-seeking behaviours were maintained or dropped during brief exposure. Dropping them improved the subsequent test outcomes, supporting the importance of how a patient interprets the exposure experience.^[ref]

These are mechanistic investigations even though their main measurements are behavioural. Mechanism need not mean a brain scan. Manipulating a contingency, testing outcome devaluation or checking whether a learned response transfers to a new context can distinguish information-processing accounts. Conversely, a neural correlate is not automatically a mechanism: a brain response can be an effect, a compensatory process or a correlate of an unmeasured cause.

Return of fear illustrates why a single endpoint is insufficient. In context-shift experiments, fear renewed outside the extinction context despite successful response reduction during extinction. Such results motivate testing a treatment across settings, delays and new cues. They constrain an erasure interpretation and explain why learning that is acquired in the clinic may not be retrieved at home.^[ref]

Mechanism claims nevertheless require stricter tests than observing that a proposed mediator and symptoms both improve. Therapist alliance, expectations and initial severity can influence both. Measuring the candidate mediator before symptom change, controlling baseline values and experimentally manipulating that component improves causal inference. Measurement error and unmeasured mediator–outcome confounding remain problems even in a trial where treatment itself was randomised.

The best programme alternates pragmatic comparisons with targeted experiments. First establish meaningful benefit and harms, then isolate components with dismantling or factorial designs, measure proposed processes and test predicted boundary conditions. Mechanistic insight should earn its place by improving prediction, personalisation or durable treatment effects, not by supplying attractive terminology. Outcomes justify the claim that an intervention works; experiments on mechanism explain when it works, what to preserve and what to change when it fails.

Fear and anxiety share learning mechanisms, neuromodulators and defensive circuitry, but differ in how threat is specified and sustained. A useful operational distinction is an immediate response to an identified danger versus prolonged anticipation of uncertain danger. That distinction should not be mistaken for a universal division into two independent brain centres. Neuropsychopharmacology is most informative when it compares matched behavioural endpoints and identifies where and when a drug acts.

The first issue is measurement. Freezing, avoidance, autonomic changes, fear-potentiated startle and subjective reports capture different aspects of threat responding. A rat’s reduced open-arm exploration can reflect anxiety, but also altered movement or novelty preference. A smaller startle response can reflect sedation rather than reduced threat processing. It is therefore necessary to measure baseline responsiveness, locomotion and sensory function, and to distinguish acquisition, consolidation, retrieval and expression. A drug administered only at testing does not establish an effect on the original learning.

An influential rat experiment compared potentiation of acoustic startle by a conditioned threat cue with enhancement during sustained bright illumination. Local AMPA receptor antagonism in the central nucleus of the amygdala disrupted the conditioned-cue effect, whereas antagonism in the bed nucleus of the stria terminalis disrupted the light-enhanced effect. The basolateral amygdala contributed to both. This is stronger evidence for differentiation than comparing unrelated assays because the measured reflex was shared. However, conditioning history, stimulus properties and duration differed together, so the result does not isolate duration or uncertainty as the sole cause of the dissociation.^[ref]

The amygdala and BNST belong to interacting networks receiving cortical and other inputs and influencing hypothalamic and brainstem outputs. The hippocampus supplies contextual information and prefrontal cortex can influence threat regulation and extinction retrieval. Subdivisions and projection-defined populations within the extended amygdala can differ in function. A general claim that the amygdala produces all fear and the BNST produces all anxiety consequently ignores shared pathways, task dependence and cellular heterogeneity.

Fast inhibitory signalling supplies an important pharmacological comparison. Many benzodiazepines positively modulate susceptible GABA-A receptors, but anxiolysis must be distinguished from sedation and amnesia. A controlled human crossover study compared predictable-cue, unpredictable-threat and no-threat conditions. Alprazolam reduced sustained contextual startle enhancement at the effective tested treatment condition while leaving phasic cue potentiation relatively unaffected. The design included an active sedating comparison as well as placebo. This supports psychopharmacological differentiation between sustained and phasic measures; it does not prove absolute drug selectivity for a subjective state or show that every clinical anxiety presentation has the same mechanism.^[ref]

Serotonin illustrates why transmitter identity alone is insufficient. Reuptake inhibition affects multiple receptors and projection targets, and early effects can differ from adaptations after repeated treatment. In mice, a dorsal-raphe projection to the BNST recruited a serotonin-sensitive local circuit and promoted selected threat-related behaviours. This provides a pathway-specific explanation for an anxiogenic effect of increasing serotonin signalling, compatible with different effects at other targets. It is not evidence that serotonin uniformly causes anxiety or that rodent threat responses establish the clinical time course of an SSRI.^[ref]

Receptor subtype and developmental timing also matter. The same receptor class can act as an autoreceptor controlling raphe output or on non-serotonergic target neurons. Norepinephrine, corticotropin-releasing hormone and other modulators interact with these systems rather than map one-to-one onto fear or anxiety. Local circuit effects should not be inferred from circulating hormone concentrations. A mechanistic explanation should state the receptor, target, timescale and outcome, not merely whether a brain-wide chemical level rose or fell.

Learning about safety supplies both a shared mechanism and a therapeutic distinction. In extinction learning, an expected aversive outcome is omitted; reduced responding can reflect new inhibitory or contextual knowledge rather than deletion of the original association. In rats, the NMDA receptor partial agonist D-cycloserine facilitated later reduction of conditioned startle when combined with extinction training. Its effect depended on learning conditions rather than acting simply as an acute suppressant of every defensive response. This motivates a learning-adjunct strategy, but the animal result alone cannot establish clinical efficacy.^[ref]

Anxiety about uncertain contexts can involve more than a response to one cue: broad threat generalization, avoidance that prevents corrective experience, and context-dependent retrieval may sustain it. Conversely, a sharply defined learned cue can acquire persistent control. Exposure therapy therefore cannot be reduced to suppressing an output on one occasion. An intervention that changes expression without improving subsequent safety learning might have a different long-term effect from one that changes what is retained. Renewal after extinction also predicts that improvement in one context need not transfer automatically to another.

The strongest comparison is thus dimensional and mechanistic. Fear and anxiety share synaptic plasticity, inhibitory signalling and distributed threat networks, while particular temporal and informational demands recruit distinguishable components. Drug and circuit dissociations are meaningful when matched controls rule out motor or sensory explanations; they should refine this network account rather than replace it with a pair of transmitter labels. These are conclusions about evidence and experimental models, not instructions for selecting medication.

Non-human experiments have made serotonin’s role in emotion more specific: its effects depend on receptor subtype, developmental history, projection and behavioural demand. Their strength is controlled intervention at levels inaccessible in ordinary human research. Their weakness is that an experimentally altered behaviour is an operational measure, not a direct reading of human emotional experience or an entire psychiatric disorder.

Serotonin arises from heterogeneous neuronal populations and acts through multiple serotonin receptors. Manipulating synthesis, reuptake, a receptor or one projection is not interchangeable. Systemic drug administration can affect many targets, while a permanent depletion permits adaptation. Conversely, temporally restricted intervention can reveal when a pathway matters but imposes a pattern that may differ from natural activity. These distinctions make converging approaches more informative than assigning a single emotional function to the molecule.

Developmental rescue experiments demonstrate why timing matters. Mice lacking 5-HT1A receptors showed increased anxiety-like behaviour; conditional receptor expression largely in hippocampal and cortical targets rescued the measured phenotype when present during an early postnatal period, whereas adult expression alone did not provide the same rescue. This supports a developmental contribution and warns against equating a lifelong genetic perturbation with acute adult treatment. However, rescue establishes sufficiency of the introduced expression pattern under those conditions, not necessarily the endogenous receptor location’s unique necessity. Ectopic expression, altered circuitry and compensatory development remain relevant limitations.^[ref]

Local depletion in primates provides a different kind of evidence. Marmosets with prefrontal serotonin depletion perseverated on a previously rewarded visual stimulus when its contingency reversed, while retention of a previously learned discrimination and acquisition of a new one were relatively spared. These controls constrain explanations based on general inability to learn or recognize the stimuli. The result links serotonin to flexible use of changed outcomes, a process relevant to emotion regulation. Yet reversal learning is not itself a measure of sadness, fear or subjective affect, and depletion is not equivalent to an isolated physiological fluctuation.^[ref]

Optogenetic studies add temporal precision. In mice waiting for delayed rewards, timed activation of dorsal-raphe serotonergic neurons reduced premature abandonment of waiting, including on omission trials. Control experiments argued against simple motor inhibition and against the effect being merely reinforcing. This challenges an account of serotonin as only a punishment or generalized behavioural-inhibition signal. The appropriate conclusion is that activating the targeted population can promote waiting in that task; patience is still a behavioural construct, and the imposed activity does not by itself identify the natural signal’s full content.^[ref]

A pathway-specific experiment gives the complementary result. Activating serotonergic projections from the dorsal raphe nucleus to the BNST promoted selected anxiety- and fear-related behaviours. Combined anatomical, electrophysiological and pharmacological evidence implicated a local 5-HT2C receptor-sensitive circuit involving corticotropin-releasing hormone neurons. Thus raising serotonergic activity in one pathway can have a different behavioural consequence from activating another population during reward waiting. Local inhibition and disinhibition matter: transmitter effects on one cell class need not have the same sign as the pathway’s net behavioural effect.^[ref]

These examples also show how apparatus shapes the claim. Open-arm exploration measures approach–avoidance under environmental threat; conditioned freezing measures one defensive output; visual choice tasks measure outcome-guided flexibility; a reward port allows measurement of waiting and leaving. Each permits careful timing and quantitative controls, but none is a complete emotional state. Converging measures of movement, feeding, autonomic state, discrimination and learned response reduce the risk of interpreting every changed score as an emotional effect.

Species comparisons are informative when they isolate conserved functions rather than presume identical experience. Primates allow some translational similarities in prefrontal organization and complex behaviour; rodents allow larger experimental samples and finer cellular access. Strain, sex, age, housing and prior stress can influence measured phenotypes. Highly controlled laboratory conditions improve internal validity while limiting the contexts over which the result is known to generalize. Inbred animals and one aversive task cannot represent the full diversity of human affective illness.

Cell specificity creates further opportunities and limits. Targeting neurons by a serotonergic marker improves on identifying them only from spike shape or location. Nevertheless, cell populations can differ in projections and co-transmission; stimulating a cell can affect more than serotonin at one target. Terminal stimulation can recruit network or collateral effects, and a receptor antagonist can have off-target drug effects. Claims about a particular released transmitter are stronger when supported by release measurements, receptor-level tests and independent perturbations, not genetic targeting alone.

Temporal comparisons are equally important. Developmental effects concern how a circuit is established; acute effects concern its current operation; repeated pharmacological exposure may change receptor regulation and experience-dependent learning. A behavioural rescue in a genetically altered mouse therefore cannot be read as a prescription for an adult human. Nor does a transient anxiogenic effect contradict every beneficial effect of longer treatment: different times, targets and readouts are being compared.

The best use of animal work is an iterative programme. Specify a computation or response, establish a selective circuit or receptor contribution, test alternative performance explanations, and then examine corresponding predictions with human behavioural and pharmacological measures. Animal experiments have already replaced a simple “more serotonin means better mood” story with mechanistic heterogeneity. Their translational value increases when they identify that heterogeneity and its boundary conditions rather than claim that one manipulation models all emotion.

The SOP model family specifies testable principles of stimulus processing and association, but it does not yet have a uniquely established neural implementation. Its behavioural breadth should be distinguished from evidence identifying the biological counterparts of its states, transition rules and separate response systems. The strongest neurobiology concerns processes that the models require—priming, associative retrieval and differentiated response pathways—rather than a one-to-one mapping of every symbol onto a brain structure.

Ivan Pavlov’s classical conditioning tradition made stimulus history and the measured conditioned response objects of controlled experiment. The SOP model introduced by Allan R. Wagner represents stimuli as elements distributed among inactivity $I$, primary activation $A_1$ and secondary activation $A_2$. External presentation promotes inactive elements into $A_1$; activity then passes through $A_2$ before returning to inactivity. A learned associate can activate an expected event directly into $A_2$. Recently or associatively activated elements are less available for renewed primary processing, distinguishing self-generated priming from retrieval-generated priming. A contemporary quantitative analysis shows how these dynamics can generate several habituation regularities; these are simulations, not measurements of neuronal states.^[ref]

The association rules make the account more specific than a generic fading trace. In the original formulation, concurrent $A_{1,CS}$ and $A_{1,US}$ activity promotes excitation, whereas $A_{1,CS}$ with $A_{2,US}$ promotes inhibition. The Modified SOP model additionally permits learning involving a cue activated into $A_2$: matched-state combinations can strengthen excitation and mismatched-state combinations inhibition. This allows an absent cue’s association to change through retrieval, addressing retrospective revaluation. The model is therefore not simply equivalent to a reward-error equation or to synaptic fatigue.

Human causal-judgment experiments motivated an important constraint. Participants learned relations among compound cues and an outcome, then received information about a companion cue without the target. Retrospective changes in judgments depended on the consistency of earlier within-compound pairings. This supports a role for learned cue–cue relations in revaluation, but the behavioural result does not identify synapses implementing the modified state-pair rules. Other retrieval or inference models can also use knowledge of those relations.^[ref]

Neural adaptation alone is insufficient to explain retrieval-generated effects. A transient reduction in response to a repeated physical stimulus could result from receptor adaptation, local synaptic dynamics or wider circuit changes, whereas context-specific long-term priming requires an account of the context’s learned relation to the event. A biological test must distinguish an unfamiliar stimulus from an unexpected combination of familiar stimuli and control attention, orienting and stimulus exposure. Reduced firing cannot simply be labelled $A_2$: the theory permits secondary activity to be behaviourally silent or have a response-system-dependent effect.

Hippocampal lesion experiments provide evidence at that process level. Rats learned audiovisual sequences in which particular sounds preceded particular lights. Switching the familiar sound–light combinations renewed visual orienting in controls but not in hippocampal-lesioned animals, despite relatively preserved habituation to visual stimuli and evidence of sequence associations. This implicates the hippocampus in associative mismatch rather than novelty alone. It is compatible with a contribution to expectation or retrieval, but does not uniquely show that the hippocampus is $A_2$, nor that every SOP model process is hippocampal.^[ref]

Receptor perturbation further separates short- and long-term components. Mice lacking the GluA1 AMPA-receptor subunit showed impaired short-term spatial novelty performance but enhanced long-term performance under the tested interval conditions. Manipulating exposure and test intervals helped distinguish rapid recency-dependent effects from longer-lasting learning. This is consistent with separable processes of the kind emphasized by the SOP model, rather than an undifferentiated stronger-versus-weaker memory. Nevertheless, a lifelong mutation can alter development and network function, and task dependence prevents identifying GluA1 with a single abstract transition parameter.^[ref]

Associative access to an absent outcome has additional circuit support. In rat sensory preconditioning, orbitofrontal inactivation impaired behaviour guided by an indirectly inferred outcome while sparing behaviour supported by the directly reward-paired cue. The manipulation also altered learning when inferred value normally acted as a blocker. This shows that retrieved associative structure can influence both performance and new learning. It is relevant to the demands of Modified SOP model, but does not demonstrate that the neural representation is in exactly $A_2$ or that its plasticity has the model’s stipulated sign.^[ref]

The Affective extension of SOP, developed by Allan R. Wagner and Susan E. Brandon, distinguishes sensory-specific and emotive components with different processing time courses and response consequences. Behavioural experiments in rabbits showed modulation of a discrete conditioned eyeblink by another putatively emotive conditioned stimulus. Such dissociations motivate separate response components. They do not locate a complete emotive representation in one nucleus. Basic conditioned-eyelid experiments independently implicated cerebellar nuclear circuitry through lesions, recordings and stimulation, illustrating why a motor conditioned response cannot simply be assigned to the same mechanism as every autonomic or emotional effect.^[ref][ref]

The remaining challenge is discriminative implementation. A candidate neural model should specify what an element is, how direct and retrieved activity differ, how relevant overlap controls plasticity, and how sensory and affective components affect separate outputs. Manipulating receptor function or recording reactivation is not enough unless alternative mechanisms make different predictions. Neuromodulators could regulate transition rates, representation selection or plasticity, but there is no justified general identity such as “dopamine is $A_1$” or “serotonin is $A_2$.” Multiple biological mechanisms could realize the same functional state description.

The SOP model family is therefore a valuable framework connecting stimulus history, expectation and response organization. Primary lesion, receptor and inactivation evidence supports several component processes. Its comprehensive behavioural ambitions exceed what is currently established about its precise neurobiology; the next useful experiments distinguish direct activation from retrieved activation and test the associated plasticity rules, rather than merely find a neural correlate of one familiar behavioural effect.

A receptor responding to serotonin. Subtypes differ in signalling and distribution, so increasing transmitter availability can affect several mechanisms at once.

An essential amino acid and precursor for serotonin synthesis. A depletion challenge is an experimental intervention with limitations as a model of ordinary disease.